SCHEDULE 13G/A: William Blair Investment Management Discloses 4.9% Passive Stake in Amicus Therapeutics

William Blair Investment Management, LLC has filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in Amicus Therapeutics, Inc. as of March 31, 2025.

Summary

• William Blair Investment Management, LLC, an investment adviser based in Chicago, IL, has filed a Schedule 13G/A with the SEC.
• The filing indicates that William Blair Investment Management, LLC beneficially owns 14,778,651 shares of Common Stock in Amicus Therapeutics, Inc.
• This ownership represents 4.9% of the class of securities, falling just below the 5% threshold that often triggers more detailed reporting.
• The shares are held with sole voting power over 13,711,815 shares and sole dispositive power over all 14,778,651 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Amicus Therapeutics, Inc.

Sentiment

Score: 5

Explanation: Neutral filing, reporting passive beneficial ownership as required by SEC regulations. It does not contain performance data or strategic updates.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of passive ownership by an investment management firm, indicating a position in Amicus Therapeutics, Inc. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact that a significant investment firm holds a stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive ownership stake by an institutional investor, confirming their position in the company.

Key Dates

Keywords

Amicus Therapeutics, William Blair Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing